Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.
Separately, HC Wainwright upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 10th.
View Our Latest Research Report on GLX
Bradmer Pharmaceuticals Stock Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- What is the Euro STOXX 50 Index?
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- High Flyers: 3 Natural Gas Stocks for March 2022
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
